Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company whose news flow centers on the treatment and prevention of cancer. Company announcements frequently highlight progress in its ovarian cancer immunotherapy program and its portfolio of cancer vaccines, especially an investigational breast cancer vaccine developed in collaboration with Cleveland Clinic.
News items for ANIX often cover clinical trial milestones, such as completion of a Phase 1 trial, presentation of final data at major scientific meetings, and plans to advance programs into subsequent phases of development. For the breast cancer vaccine targeting α-lactalbumin, disclosures have included safety and immune response findings, details on trial cohorts, and steps to transfer the related IND sponsorship from Cleveland Clinic to Anixa for future trials.
Another recurring theme in Anixa’s news is its ovarian cancer CER-T (CAR-T) program, including regulatory and naming milestones. The company has reported that the World Health Organization’s International Nonproprietary Names Expert Committee approved “liraltagene autoleucel” (lira-cel) as the non-proprietary name for its FSHR-targeted CAR-T therapy, and updates often describe the ongoing first-in-human trial in recurrent ovarian cancer.
Investors and observers can also expect intellectual property updates, such as U.S. and international patent issuances that extend protection for the breast cancer vaccine technology, as well as participation in investor conferences and research-focused fireside chats. Together, these news items provide insight into Anixa’s clinical progress, collaboration activities with institutions like Cleveland Clinic and Moffitt Cancer Center, and the evolution of its immuno-oncology pipeline.
Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the USPTO for a key patent application covering its ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting Anti-Mullerian Hormone Receptor, Type II (AMHR2), which is considered a promising target for ovarian cancer prevention and treatment.
The vaccine, being developed in collaboration with Cleveland Clinic and the National Cancer Institute, represents a novel approach particularly focused on high-risk populations, including individuals with BRCA mutations or family history of ovarian cancer. The allowed claims specifically cover methods of administering an immunogenic composition comprising a nucleic acid encoding the AMHR2 polypeptide's extracellular domain to elicit an AMHR2-specific immune response.
Anixa Biosciences (NASDAQ: ANIX) announced that CEO Dr. Amit Kumar will present at the 2025 CAGLA NeauxCancer Conference on March 28th, 2025, at 10:00 AM CDT in New Orleans. The presentation, taking place at The Roosevelt Hotel, will showcase Anixa's innovative cancer treatment programs.
Dr. Kumar will provide updates on the company's cutting-edge CAR-T therapy for solid tumors and novel cancer vaccine initiatives. The presentation will highlight Anixa's progress in clinical development and their approach to advancing next-generation immunotherapies in cancer care.
The CAGLA NeauxCancer Conference, scheduled for March 27-29, 2025, brings together oncology researchers, industry executives, investors, and medical professionals to discuss breakthrough developments in cancer treatment.
Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced its 2025 Annual Meeting of Stockholders scheduled for Thursday, March 20, 2025, at 10:00 a.m. Pacific Time. The meeting will be conducted in a virtual format.
The event will feature two main segments: first, the formal business and voting portion, followed by an investor presentation and corporate update by Chairman and CEO Dr. Amit Kumar. A question-and-answer session will conclude the meeting. The company has made the meeting accessible to all interested parties through their virtual platform at www.virtualshareholdermeeting.com/ANIX2025.
Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Pam Garzone, their Chief Development Officer, will participate as a panelist at the Alliance for Cancer Gene Therapy (ACGT) Summit 2025. The event will take place on March 19-20, 2025, at the Alexandria Center for Life Science in New York City.
Dr. Garzone will join the Gynecologic and Breast Cancers panel on March 19th from 11:15 AM to 12:15 PM ET. The discussion will focus on advancements in cell and gene therapy, including Anixa's CAR-T therapy for ovarian cancer and its potential impact on gynecologic and breast cancers.
Dr. Amit Kumar, Chairman and CEO of Anixa, emphasized the importance of sharing insights at the summit to advance discussions on gene-based treatments for cancer. The ACGT Summit will gather leading physician scientists working on developing curative cell and gene therapies for solid tumor cancers.
Anixa Biosciences (NASDAQ: ANIX) has completed dosing the final patient in the third cohort of its Phase 1 clinical trial for a novel CAR-T therapy targeting recurrent ovarian cancer, conducted in partnership with Moffitt Cancer Center. The third cohort received one million CAR-positive cells per kilogram, a tenfold increase from the first cohort.
The trial's fourth cohort is set to begin after a 30-day safety verification period, with plans to increase dosage by another factor of three. The therapy targets the follicle-stimulating hormone receptor (FSHR), which is exclusively expressed on ovarian cells, tumor vasculature, and certain cancer cells.
A recent protocol amendment allows eligible patients to receive a second dose if beneficial and expands enrollment criteria to include rare ovarian cancer subtypes. The first-in-human trial (NCT05316129) focuses on adult women with recurrent ovarian cancer who have progressed after at least two prior therapies, evaluating safety, maximum tolerated dose, and efficacy.
Anixa Biosciences' breast cancer vaccine was featured on Fox News' "America Reports," highlighting its potential to revolutionize breast cancer prevention by targeting the disease at its earliest stages. The vaccine trains the immune system to recognize α-lactalbumin, a protein expressed during lactation and in breast cancer cells, potentially providing preemptive protection against emerging tumors.
The ongoing Phase I clinical trial, conducted with Cleveland Clinic and funded by the U.S. Department of Defense, shows promising progress with a strong safety profile. The vaccine has been well tolerated, with protocol-defined immune responses observed in over 70% of patients. A Phase 2 study in the neoadjuvant setting is planned to begin in 2025.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, expressed optimism about the vaccine's potential impact in reducing the incidence of triple-negative breast cancer and other breast cancers.
Anixa Biosciences (NASDAQ: ANIX) announced that its CAR-T therapy for ovarian cancer, developed with Moffitt Cancer Center, was featured in Breaking Cancer News. The therapy, exclusively licensed from The Wistar Institute, targets the follicle-stimulating hormone receptor (FSHR) protein found on ovarian cancer cells.
The clinical trial is being led by Dr. Robert Wenham and Dr. Monica Avila from Moffitt Cancer Center. This innovative approach aims to revolutionize ovarian cancer treatment by using the body's immune system to attack tumors directly. The article discusses potential study expansion to evaluate repeat dosing and explores broader implications for CAR-T therapy in solid tumors.
Anixa Biosciences (NASDAQ: ANIX) and Moffitt Cancer Center have received approval for a protocol amendment in their ongoing ovarian cancer CAR-T therapy clinical trial. The amendment brings two significant changes: it allows eligible patients to receive a second dose of CAR-T therapy without requiring individual IND approvals, and expands enrollment eligibility to include patients with sex cord-stromal tumors (SCSTs) and Sertoli Leydig cell tumors (SLCTs).
Previously, Anixa and Moffitt had secured a single patient IND approval for an additional dose for a patient whose biopsy showed cellular infiltration and necrosis, indicating biological activity of the CAR-T therapy. The amendment aims to optimize treatment outcomes for patients with ovarian cancer by providing more flexibility in dosing and expanding the types of ovarian cancers that can be treated.
Anixa Biosciences (NASDAQ: ANIX) CEO Dr. Amit Kumar discussed the company's innovative cancer treatments in an Alpha Wolf Trading interview. The company is developing two main programs: a CAR-T cell therapy for ovarian cancer and a breast cancer vaccine.
The CAR-T therapy aims to overcome challenges in treating solid tumors, distinguishing it from traditional approaches that work primarily on blood cancers. The breast cancer vaccine targets triple-negative breast cancer (TNBC), the most aggressive form of the disease.
The company emphasizes its capital-efficient business model, maintaining a low burn rate through strategic partnerships with research institutions. This approach reduces the need for extensive in-house R&D expenditures while advancing their therapeutic developments.
Anixa Biosciences (NASDAQ: ANIX) has announced its participation in the 18th Annual European Life Sciences CEO Forum, scheduled for February 26-27, 2025, at the Hilton Zurich Airport Hotel in Switzerland. Mike Catelani, President and CFO, will present on February 27 at 10:40 AM CET.
The presentation will focus on Anixa's pipeline updates, including their:
- CAR-T therapy for ovarian cancer (collaboration with Moffitt Cancer Center)
- Breast cancer vaccine (partnership with Cleveland Clinic)
- Expanding portfolio of cancer vaccine programs
The conference brings together key executives, investors, and industry experts from the global life sciences sector to discuss innovations, investment trends, and partnership opportunities. Mr. Catelani will also conduct one-on-one meetings with potential partners and investors to discuss strategic initiatives and clinical advancements in their innovative therapies.